A Prospective, 16 Week, Phase IV Study to Evaluate Safety, Tolerability and Effectiveness in Patients With Severe Dementia of the Alzheimer's Type Exposed to Rivastigmine (Exelon)15cm2 Transdermal Patch
Latest Information Update: 04 Jun 2024
At a glance
- Drugs Rivastigmine (Primary)
- Indications Dementia
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals
- 24 Jan 2023 Status changed from active, no longer recruiting to completed.
- 21 Dec 2022 Status changed from recruiting to active, no longer recruiting.
- 23 Feb 2022 Planned End Date changed from 30 Dec 2022 to 2 Jan 2023.